RE:RE:RE:RE:Trading below PP Here you go Algernon, sorry for the delay, I had to read back through 100s of posts of luv hourses talking about SCIENCE and free range chickens
Algernon wrote: Bellus Health is the best comparison to Algernon because they both are pursuing Chronic Cough. The other company you threw in the mix in not a comparison to Algernon. Sure, your other pick has thrown it's hat in the COVID ring but what biotech hasn't? I can't make heads or tails out of "ARCH's" pipeline. IMO, the website is not very user friendly in that regard. So, who knows where any of ARCH's compounds are in the clinical trial process? It appears most are still preclinical. In stark contrast, Algernon is a clinical stage company - period. Meaning, ALL it's lead compounds are in the human clinical trial process, and more importantly ALL compounds are past Phase 1. As to the "patents' at Algernon, you need to dig deeper by reviewing multiple filings at SEDAR. It's all there. Algernon has told shareholders numerous times that Provisional Patents & Markush Patents have been filed for ALL lead compounds. Although that may not be enough "proof" for some, I can't imagine such an ongoing statement being false. Algernon has also verbally expressed additional patent filings in the most recent webcasts. I suspect patent applications will continue to be updated throughout the clinical trial process for ALL lead compounds for multiple targeted diseases. The question about marketing ANY of the lead compounds has been addressed multiple times a swell. There is no issue with global distribution of NP-120 (Ifenprodil) for any of it's targeted diseases. Nor is it an issue with ANY of the other lead compounds. You must understand ALL lead compounds by Algernon are only approved in a limited number of countries (Japan, Russia, Ukraine) . Outside of those few countries of 195 countries around the world, ALL lead compounds are like new and used for "new drug indications". The provisional & Markush patents will protect Algernon's intellectual property rights and monetary efforts. As far as who owns what, insider this and that, it all comes out in the rinse. Meaning, what matters is data results. Algernon will have plenty of data results from around the world (Canada, USA, Australia, South Korea) between now and Q3 2020. At which time, all the petty comparisons and speculation flies out the window. Algernon came out of nowhere in a short period of time. COVID-19 may put Algernon front and center on the world stage with its Phase 2b/3 clinical trial. That's another step ahead of Bellus and your ARCH comparison.